Press Releases

May 12, 2016
Opiant Pharmaceuticals, Inc. Announces Appointments of Grabrielle A. Silver, M.D., and Ann MacDougall to Board of Directors (PDF)

May 6, 2016
Opiant Pharmaceuticals, Inc.’s Parter, Adapt Pharma Limited, Submits New Drug Submission for Naloxone Nasal Spray to Health Canada (PDF)

March 16, 2016
Opiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2016 Financial Results and Provides Corporate Update (PDF)

March 7, 2016
Opiant Pharmaceuticals, Inc. Announces Ticker Symbol Change to “OPNT” (PDF)

March 7, 2016
Opiant Pharmaceuticals, Inc., Receives $2.5 Million Milestone Payment Following Adapt Pharma Limited’s First Commercial Sale of Narcan® (Naloxone Hydrochloride) Nasal Spray in the U.S. (PDF)

February 17, 2016
Opiant Pharmaceuticals, Inc., Convenes Medical Advisory Board to Support Development of Pharmacological Treatments for Substance Use, Addictive and Eating Disorders (PDF)

February 17, 2016
Lightlake Therapeutics Inc. Announces Name Change to Opiant Pharmaceuticals, Inc. (PDF)

February 16, 2016
Lightlake Therapeutics Inc. Expands Drug Development Capabilities by Appointing Mark Ellison, Ph.D., as Executive Vice President Development, Manufacturing and Quality

January 27, 2016
Lightlake Therapeutics Inc.Announces Adapt Pharma Limited to Offer All U.S. High Schools a Free Narcan® (Naloxone Hydrochloride) Nasal Spray and Fund School-Based Opioid Overdose Education

January 19, 2016
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Facilitates NARCAN® (Naloxone Hydrochloride) Nasal Spray Access to 62,000 State and Local Public Entities

December 23, 2015
Lightlake Therapeutics Inc. Announces Collaboration With NIDA and the Perelman School of Medicine at the University of Pennsylvania

December 15, 2015
Lightlake Therapeutics Inc. Receives Milestone Payment for U.S. Food and Drug Administration Approval of NARCAN(R) (Naloxone Hydrochloride) Nasal Spray

November 19, 2015
NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration

October 1, 2015
LLTP Receives Second Funding Commitment From a Prominent International Research and Development Foundation

September 25, 2015
LLTP Announces FDA Accepts for Review Adapt Pharma Limited’s NARCAN(R) (Naloxone Hydrochloride) Nasal Spray

July 29, 2015
LLTP Announces Adapt Pharma Limited Submits NDA To FDA For Narcan® (naloxone) Nasal Spray

June 3, 2015
LLTP Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone

April 22, 2015
LLTP Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study

February 17, 2015
LLTP Announces Fast Track Designation From FDA For Intranasal Naloxone Treatment To Reverse Opioid Overdose

February 9, 2015
LLTP Appoints Arvind Agrawal Executive Vice President, Medical Affairs

December 16, 2014
LLTP Announces Licensing Deal With Adapt Pharma Limited Subsidiary

December 4, 2014
Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)

October 2, 2014
LLTP Announces Closing of Investments in Two Products

September 23, 2014
Dr. David Sinclair, LLTP’s Chief Science Officer Emeritus, Featured in Alcoholism Documentary

July 30, 2014
LLTP Receives Funding Commitment From a Prominent International Research and Development Foundation

July 23, 2014
LLTP Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse

July 9, 2014
LLTP Signs Agreement with Manufacturer for Opioid Overdose Reversal Treatment

February 3, 2014
Phillip Seymour Hoffman Didn’t Have to Die (“Time”)

December 3, 2013
Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose a Promising Treatment

November 20, 2013
LLTP to Present at 6th Annual LD Micro Conference

September 24, 2013
LLTP Commences Two  Week Patient Trial with NIDA for Treatment of Opioid Overdose

September 3, 2013
Attention Opioid Addicts: Studies Could Save You from Fatal Overdose (“Forbes”)

August 21, 2013
LLTP Announces Partnership with NIDA to Treat Opioid Overdose

August 21, 2013
LLTP Partners with NIDA to Expand Access to Opioid Overdose Medication (“NIDA”)

August 5, 2013
LLTP Retains KCSA as Corporate Communications Advisors

June 27, 2013
Video of LLTP’s CEO, Dr. Roger Crystal, at OneMedForum

June 18, 2013
LLTP to Present at 4th Annual OneMedForumNY

April 24, 2013
LLTP to Develop Opioid Drug Treatment with National Institute on Drug Abuse

April 4, 2013
LLTP Provides Guidance on Company Operations

March 27, 2013
LLTP Presents Clinical Trial Results to APA

November 29, 2012
LLTP Appoints Kevin Pollack New CFO

September 24, 2012
LLTP Appoints Dr. David Kessler as Strategic Advisor

LLTP Announces Positive Preliminary Phase II Clinical Trial Results of Binge

May 3, 2012
Eating Disorder Treatment

April 17, 2012
LLTP Appoints Pollack to Board

February 1, 2012
LLTP Responds to Questions About Trading Activity

January, 2012
LLTP Applies Patented Technology to New Treatment for PMS Overeating

January 3, 2012
LLTP Discusses New Opiate Overdose Treatment with King’s College, London

October 5, 2011
LLTP to Conduct Phase II Testing of New Bulimia Nervosa Treatment at King’s College, London

August 24, 2011
LLTP Set to Begin Phase II Clinical Trials of Binge Eating Disorder Treatment

February 1, 2011
LLTP Takes Safer Approach to Obesity